The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN)
Abstract
In Brief Purpose: Intravitreal bevacizumab (Avastin; Genentech Inc., San Francisco, CA) is a new treatment for age-related macular degeneration. The aim of this study was to evaluate retinal penetration and toxicity of bevacizumab. Methods: Ten albino rabbits were injected intravitreally with 0.1 mL (2.5 mg) of Avastin into one eye and 0.1 mL saline into the fellow eye. The electroretinogram (ERG) was recorded after 3 hours, 3 days, and 1, 2, and 4 weeks. The visual evoked potential (VEP) was recorded after 4 weeks. Confocal immunohistochemistry was used to assess retinal penetration. Results: The ERG responses of the control and experimental eyes were similar in amplitude and pattern throughout the follow-up period. The flash VEP responses of the experimental eyes were of normal pattern and amplitude and did not differ from those recorded by stimulation of the control eye alone. Full thickness retinal penetration was present at 24 hours and was essentially absent at 4 weeks. Conclusions: Bevacizumab was found to be nontoxic to the retina of rabbits based on electrophysiologic studies. Full thickness retinal penetration may explain observed clinical effects of intravitreal bevacizumab. Although it is difficult to directly extrapolate to humans, our study supports the safe use of intravitreal bevacizumab injection. Ten rabbits were injected intravitreally with 2.5 mg of bevacizumab. Electroretinogram and visual evoked potential were recorded after various time intervals. Bevacizumab was found to be nontoxic to the rabbit retina, and to penetrate full thickness retina at 24 hours after injection. This study supports the safe use of intravitreal bevacizumab injection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Cited by
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Mechanisms of macular edema: Beyond the surface
Daruich, A., Matet, A., Moulin, A., Kowalczuk, L., Nicolas, M., Sellam, A., Rothschild, P.-R., Omri, S., Gélizé, E., Jonet, L., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.10.006 · Cited by 708
Fung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
INTRAVITREAL BEVACIZUMAB (AVASTIN) THERAPY FOR PERSISTENT DIFFUSE DIABETIC MACULAR EDEMA
HARITOGLOU, C., KOOK, D., NEUBAUER, A., WOLF, A., PRIGLINGER, S., STRAUSS, R., GANDORFER, A., ULBIG, M., & KAMPIK, A. (2006) · Retina · doi:10.1097/01.iae.0000247165.38655.bf · Cited by 453
Metadata
- Authors
- SHAHAR, J., AVERY, R. L., HEILWEIL, G., BARAK, A., ZEMEL, E., LEWIS, G. P., JOHNSON, P. T., FISHER, S. K., PERLMAN, I., & LOEWENSTEIN, A.
- Venue
- Retina
- Published
- 2006-03
- Volume
- 26
- Issue
- 3
- Pages
- 262-269
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1988233478
- Cited by
- 350
- References
- 2
- FWCI
- 50.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN). https://app.cochat.ai/papers/10.1097/00006982-200603000-00002
- The paper
- SHAHAR, J., AVERY, R. L., HEILWEIL, G., BARAK, A., ZEMEL, E., LEWIS, G. P., JOHNSON, P. T., FISHER, S. K., PERLMAN, I., & LOEWENSTEIN, A. (2006). ELECTROPHYSIOLOGIC AND RETINAL PENETRATION STUDIES FOLLOWING INTRAVITREAL INJECTION OF BEVACIZUMAB (AVASTIN). Retina. https://doi.org/10.1097/00006982-200603000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.